Connection

Fengcai Zhu to Human papillomavirus 18

Back to Details
This is a "connection" page, showing publications Fengcai Zhu has written about Human papillomavirus 18.
Fengcai Zhu
Connection Strength
1.001
Human papillomavirus 18
  1. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial. Cancer Med. 2019 10; 8(14):6195-6211.
    View in: PubMed
    Score: 0.802
  2. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women. Sci China Life Sci. 2020 Apr; 63(4):582-591.
    View in: PubMed
    Score: 0.200
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.